Medicare Part D

In a new analysis, KFF finds that 3.6 million people with Medicare could be eligible for coverage of Wegovy (semaglutide) now that the Food and Drug Administration has approved the use of the anti-obesity drug to reduce the risk of heart attacks and stroke in certain patients. This change potentially…

KFF’s latest Health Tracking Poll examines the public’s views and use of an an increasingly popular class of prescription drugs used for weight loss and to treat diabetes or prevent heart attacks or strokes. The poll finds 12% of adults report having taken one of these GLP-1 drugs, which include Ozempic, Webovy and Mounjaro. This includes 6% who say they are currently taking one of the drugs.

About one in eight adults (12%) say they have taken one of an increasingly popular class of prescription drugs known as GLP-1s that are used for weight loss and to treat diabetes and reduce the risk of heart disease and stroke, a new KFF Health Tracking Poll finds. This includes…

This brief analyzes 2024 Medicare Part D enrollment, premiums, and cost sharing. The analysis highlights the continued growth in Medicare Advantage enrollment in the Part D marketplace and substantially higher average monthly premiums for stand-alone Part D drug plan coverage. Changes to the Part D benefit included in the Inflation Reduction Act are helping to lower out-of-pocket costs for patients but could also contribute to higher-priced Part D coverage.

On Thursday, August 11, a panel of KFF experts held a web briefing to explain the provisions in the Inflation Reduction Act and how they would affect people and federal health spending.

This Policy Insight draws on the experiences of Medicare beneficiaries during Medicare’s annual enrollment period to consider whether consumers with health insurance coverage through the Affordable Care Act’s new marketplaces will shop for a better deal during their open enrollment season.

This brief focuses on the stand-alone Medicare Part D prescription drug plan marketplace and its somewhat uncertain future, in light of recent trends in plan availability and the potential for another year of premium increases in 2026, in part depending on what the Trump administration decides to do with the temporary Part D premium stabilization demonstration. The brief explains why the stability of the PDP market matters, both for people in traditional Medicare who want prescription drug coverage but also for the viability of traditional Medicare as an option vis a vis Medicare Advantage.

These charts highlight data from a poll on Seniors and the Medicare Prescription Drug Benefit, conducted jointly by the Kaiser Family Foundation and the Harvard School of Public Health between November 9 and 19, 2006. It included a nationally representative sample of 718 seniors, including 275 who reported being enrolled…

The survey, which assessed seniors’ views of and experiences with the Medicare drug benefit, was conducted November 9-19 by the Kaiser Family Foundation and the Harvard School of Public Health. It included a nationally representative sample of 718 seniors, including 275 who reported being enrolled in a Medicare drug plan.…

This chartpack is part of a survey by the Kaiser Family Foundation and Harvard School of Public Health that examines public opinion on the Medicare prescription drug debate. The survey, a follow-up to a broader, more comprehensive survey released in June 2003 about the Medicare program and proposed changes, finds…